Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

Bayer grabs Chinese okay for CKD therapy Kerendia

Novartis eyes earlier use of PD-1 drug in oesophageal cancer

A 3-step guide to addressing difficult issues and creating mutual solutions

AZ takes aim at BMS’ lead in neoadjuvant NSCLC

Blueprint cashes in on the past to build its future

pemigatinib

cancer_pixabay_royalty_free

Market Access/ News/ News

NICE changes its mind on rare bile duct cancer drug from Incyte

Phil Taylor cholangiocarcinoma, HEOR, Incyte, NICE, Oncology, Pemazyre, pemigatinib, targeted oncology 0 Comment

Incyte’s Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer,

X

NICE changes its mind on rare bile duct cancer drug from Incyte

https://pharmaphorum.com/news/nice-changes-its-mind-on-rare-bile-duct-cancer-drug-from-incyte/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Liver injuries prompt clinical hold on Sanofi BTK drug
Novartis eyes earlier use of PD-1 drug in oesophageal cancer
AZ takes aim at BMS' lead in neoadjuvant NSCLC
Bayer grabs Chinese okay for CKD therapy Kerendia
Blueprint cashes in on the past to build its future

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com